Trial Profile
Combination therapy of Eribulin, Trastuzumab and Pertuzumab for the treatment of patients with previously treated advanced HER2-positive breast cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Sep 2017
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- 27 Sep 2017 Status changed from active, no longer recruiting to completed.
- 27 Jan 2016 New trial record
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium